Our liposome platform is composed of four drug encapsulation methods: Lipo-Omni®, Hydro-Omni® Lipo-X® and Duo-Omni®. A specific drug encapsulation technology is selected based on the physicochemical properties of a compound of interest. Our liposome product exhibits the following features: - High drug encapsulation efficiency - Excellent product stability - Controlled drug release profile - Improved drug delivery specificity Because our product candidates use already approved active pharmaceutical ingredients (APIs), we are eligible to utilize the streamlined 505(b)(2) regulatory pathway for approval in the United States and a similar pathway worldwide. Based on our proprietary technology platforms, we have assembled a diverse liposome product portfolio targeting the key areas of unmet medical needs (e.g., Oncology and cancer drug resistance, inflammation disorders, infectious disease and pain management).
